Authors: Granberry, Mark C.; Fonseca, Vivian A.

Source: American Journal of Cardiovascular Drugs, Volume 5, Number 3, 2005 , pp. 201-209(9)

Publisher: Adis International

Abstract:

Patients with type 2 diabetes mellitus have a greater risk of cardiovascular disease than nondiabetic individuals. These patients are often insulin resistant and have an associated clustering of risk factors that contribute to cardiovascular disease. The risk factors include dyslipidemia, hypertension, altered hemostasis, and chronic inflammation. A primary objective in the management of type 2 diabetes mellitus is normalization of blood glucose levels; however, some of the oral drugs used to control blood glucose levels have significant effects on these risk factors. In this article, we review the current data involving the modification of these cardiovascular risk factors by the biguanide (metformin), the thiazolidinediones (troglitazone, rosiglitazone, and pioglitazone), the -glucosidase inhibitors (miglitol, acarbose), and the insulin secretagogs (glyburide [glibenclamide], glipizide, chlorpropamide, tolbutamide, tolazamide, glimepiride, repaglinide, and nateglinide). Generally, the thiazolidinediones improve hemostasis and endothelial function and reduce blood pressure, while having variable effects on dyslipidemia. Metformin improves dyslipidemia and altered hemostasis and decreases plasma C-reactive protein levels with little or no effect on blood pressure. Data on the effects of the -glucosidase inhibitors and insulin secretagogs are sparse; however, these drugs appear to have little or no effect on cardiovascular risk factors.

Keywords: Diabetes mellitus; Metabolic syndrome; Cardiovascular disorders; Pioglitazone; Rosiglitazone; Peroxisome proliferator activated receptor gamma a; Metformin; Biguanides

Document Type: Review article

Affiliations: 1: 3 College of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA

Publication date: 2005-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Cardiovascular Medicine ,  Pharmacology
• By this author: Granberry, Mark C. ;  Fonseca, Vivian A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers